BioMarin Pharmaceutical (BMRN) Reports Mixed Q2 Earnings; Guides FY08
More News related to BMRN
- BioMarin to Present at the Piper Jaffray Healthcare Conference
- BioMarin Announces the Planned Retirement of Dr. Emil Kakkis, Chief Medical Officer
- Citi Upgrades BioMarin Pharmaceutical (BMRN) to Buy
- Data to Be Presented at 58th Annual Meeting of The American Society of Human Genetics
- BioMarin to Present at the Credit Suisse Healthcare Conference
More News related to Earnings
- Hallwood Group Declares Cash Dividend on Common Stock
- Doug Franklin to Lead Cox Newspapers as Executive Vice President
- ProLogis Comments on Recent Downgrades
- Transatlantic Reinsurance Company Elects New Officers
- Medical Properties Trust Declares Dividend
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) reports Q2 EPS of $0.10, versus the analyst estimate of $0.03. Revenues for the quarter were $64.2 million, versus the consensus of $66.3 million.
Sees FY08 revs of $288-$326 million, versus the consensus of $312.5 million.
Related Categories
EarningsGuidance
Stocks Mentioned
+0.39Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
